Eyluxvi
Aflibercept biosimilar developed by Alteogen, development code ALT-L9. Reference product Eylea.
Brands by market: Eyluxvi (EU) · Commercial partner or holder: Biolitec pharma (EU holder)
FDAnot listed
EMASep 2025authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Eyluxvi
European Medicines Agency and European CommissionApprovedBrand
Eyluxvi
Holder or applicant
Biolitec pharma Limited Zweigniederlassung Jena
Pathway
Centralised (Article 10(4))
Approved
Sep 2025
Application or permission
EMEA/H/C/006282
Presentations
see SmPC
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMASep 2025Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning aflibercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.